---
title: "Trulieve Cannabis Posts Profitable Q1 2026, Expands Footprint"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285537291.md"
description: "Trulieve Cannabis reported profitable Q1 2026 results with $287 million in revenue, a 59% gross margin, and a net income of $2 million. The company expanded its Florida retail network and strengthened liquidity with a $60 million private placement. Following the Trump Administration's rescheduling of medical marijuana to Schedule III, Trulieve is filing DEA registration applications for 206 dispensaries. Analysts rate TRUL stock as a Buy with a C$15.00 price target, though concerns about valuation and regulatory risks remain."
datetime: "2026-05-07T11:09:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285537291.md)
  - [en](https://longbridge.com/en/news/285537291.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285537291.md)
---

# Trulieve Cannabis Posts Profitable Q1 2026, Expands Footprint

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

An update from Trulieve Cannabis ( (TSE:TRUL) ) is now available.

Trulieve Cannabis reported first quarter 2026 results on May 7, 2026, posting revenue of $287 million, 59% gross margin, and positive net income of $2 million, with adjusted EBITDA of $100 million and strong cash generation, including $56 million from operations and $42 million of free cash flow. The company expanded its Florida retail network, grew its rewards program to one million members, strengthened liquidity with a $60 million private placement, and is moving quickly to capitalize on the Trump Administration’s rescheduling of medical marijuana to Schedule III by filing DEA registration applications for 206 state-licensed medical dispensaries, underscoring its positioning to benefit from evolving U.S. federal cannabis policy.

MainPoint1: Trulieve delivered profitable Q1 2026 results with solid margins and cash flow.  
MainPoint2: It expanded its retail footprint and advanced DEA registration after Schedule III rescheduling.

The most recent analyst rating on (TSE:TRUL) stock is a Buy with a C$15.00 price target. To see the full list of analyst forecasts on Trulieve Cannabis stock, see the TSE:TRUL Stock Forecast page.

**Spark’s Take on TRUL Stock**

According to Spark, TipRanks’ AI Analyst, TRUL is a Neutral.

The score is driven primarily by strong technical momentum (price well above key moving averages with positive MACD) and solid cash-flow-led financial performance. These strengths are tempered by weak valuation support due to negative earnings and earnings-call risks centered on near-term revenue pressure and ongoing regulatory/tax uncertainty.

To see Spark’s full report on TRUL stock, click here.

**More about Trulieve Cannabis**

Trulieve Cannabis Corp. is a leading U.S. cannabis operator focused primarily on retail sales of medical marijuana products. The company runs 240 dispensaries and more than four million square feet of cultivation and processing capacity across the United States, with a particularly dense footprint in Florida and a large medical patient customer base.

**Average Trading Volume:** 187,224

**Technical Sentiment Signal:** Buy

**Current Market Cap:** C$2.62B

### Related Stocks

- [TCNNF.US](https://longbridge.com/en/quote/TCNNF.US.md)

## Related News & Research

- [Trulieve to Open Medical Cannabis Dispensary in Belleview, Florida | TCNNF Stock News](https://longbridge.com/en/news/285201506.md)
- [Trulieve Cannabis (CNSX:TRUL): Assessing Valuation After Texas Medical Cannabis License Approval](https://longbridge.com/en/news/268863003.md)
- [Pizza Pizza Royalty slashes monthly dividend by 12.9% to CAD 0.0675 a share](https://longbridge.com/en/news/286714154.md)
- [State Cannabis Companies Rushed To Apply for DEA Registration but DEA Cannot Rewrite Marijuana Federal Register Rules With a Press Statement](https://longbridge.com/en/news/286649436.md)
- [How Investors May Respond To American Healthcare REIT (AHR) Cutting 2026 Profit Outlook After Q1 Results](https://longbridge.com/en/news/286866277.md)